AAPL 221.875 -3.5242% MSFT 427.22 -0.4219% NVDA 139.85 1.554% GOOGL 199.3225 1.6952% GOOG 201.35 1.9236% AMZN 228.7043 1.2235% META 617.385 0.7531% AVGO 239.5299 0.8802% TSLA 413.825 -2.9719% TSM 213.7392 1.0587% LLY 735.7301 1.3793% V 322.15 0.7916% JPM 261.25 0.8065% UNH 520.02 2.0127% NVO 80.28 2.0206% WMT 93.245 1.4194% LVMUY 145.13 2.1467% XOM 111.61 -0.6321% LVMHF 725.1 1.976% MA 529.315 0.8796%
AAPL 221.875 -3.5242% MSFT 427.22 -0.4219% NVDA 139.85 1.554% GOOGL 199.3225 1.6952% GOOG 201.35 1.9236% AMZN 228.7043 1.2235% META 617.385 0.7531% AVGO 239.5299 0.8802% TSLA 413.825 -2.9719% TSM 213.7392 1.0587% LLY 735.7301 1.3793% V 322.15 0.7916% JPM 261.25 0.8065% UNH 520.02 2.0127% NVO 80.28 2.0206% WMT 93.245 1.4194% LVMUY 145.13 2.1467% XOM 111.61 -0.6321% LVMHF 725.1 1.976% MA 529.315 0.8796%

Centessa Pharmaceuticals PLC ADR

Healthcare US CNTA

15.57USD
0.41(2.70%)

Last update at 2025-01-21T15:02:00Z

Day Range

14.9615.93
LowHigh

52 Week Range

4.3012.45
LowHigh

Fundamentals

  • Previous Close 15.16
  • Market Cap934.87M
  • Volume20689
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-170.97299M
  • Revenue TTM6.85M
  • Revenue Per Share TTM0.07
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-1.42

Analyst Recommendations

Financials

Income Statement

2019-12-312020-12-312021-12-312022-12-31-350M-300M-250M-200M-150M-100M-50M0M
Total Revenue
Net Income

Balancesheet

2019-12-312020-12-312021-12-312022-12-312023-12-310M50M100M150M200M250M300M350M400M450M500M550M600M
Total Assets
Total Liabilities

Change in Cash

2019-12-312020-12-312021-12-312022-12-31-200M-100M0M100M200M300M400M500M

Total Operating Cash

2019-12-312020-12-312021-12-312022-12-31-220M-200M-180M-160M-140M-120M-100M-80M-60M-40M-20M0M

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -216.95400M -380.95700M -10.66300M -5.06100M
Minority interest - - - -
Net income -216.20700M -381.07100M -11.04100M -5.28400M
Selling general administrative 55.20M 42.89M 1.14M 0.79M
Selling and marketing expenses - - - -
Gross profit - - - -
Reconciled depreciation 0.13M - 0.00000M 0.00600M
Ebit -212.26300M -379.78500M -10.44000M -5.05300M
Ebitda -207.94100M -379.75100M -10.28500M -4.93700M
Depreciation and amortization 4.32M 0.03M 0.15M 0.12M
Non operating income net other - - - -
Operating income -212.26300M -379.78500M -10.44000M -5.05300M
Other operating expenses 210.28M 138.55M 10.44M 5.05M
Interest expense 7.03M 1.17M 0.38M 0.12M
Tax provision -0.74700M - - -
Interest income - - 0.25M 0.00500M
Net interest income -7.03300M - -0.37800M -0.11300M
Extraordinary items - - - -
Non recurring - - - -
Other items - - - -
Income tax expense -0.74700M 0.11M 0.38M 0.22M
Total revenue 0.00000M - 0.00000M 0.00000M
Total operating expenses 210.28M 138.55M 10.44M 5.05M
Cost of revenue - - - -
Total other income expense net -4.69100M -1.17200M -0.22300M -0.00800M
Discontinued operations - - - -
Net income from continuing ops -216.20700M - -10.66300M -5.06100M
Net income applicable to common shares -216.20700M -381.07100M -10.66300M -5.06100M
Preferred stock and other adjustments - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 362.97M 444.31M 629.63M 11.72M 19.73M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 19.39M 3.27M 0.99M 0.00600M 0.00400M
Total liab 126.72M 108.14M 138.08M 34.14M 6.07M
Total stockholder equity 236.24M 336.17M 491.55M -22.42300M 13.66M
Deferred long term liab - - - 0.25M -
Other current liab 27.57M 24.50M 16.57M 0.92M -
Common stock 0.27M 0.27M 0.25M 25.55M -
Capital stock 0.27M 0.27M 0.25M 0.00000M -
Retained earnings -752.94500M -601.86000M -385.65300M -22.42300M -12.51100M
Other liab - - 37.74M - -
Good will - - - - -
Other assets - 5.39M 0.70M 0.55M -
Cash 128.03M 393.64M 595.08M 7.23M -
Cash and equivalents - - - - -
Total current liabilities 39.38M 38.34M 24.64M 8.62M 1.93M
Current deferred revenue - - - 1.04M -
Net debt -43.44200M -323.84400M -519.38200M -1.60000M -
Short term debt - - - 5.63M 0.54M
Short long term debt - - - 5.63M -
Short long term debt total 84.59M 69.80M 75.70M 5.63M 3.62M
Other stockholder equity 987.42M 939.26M 876.27M 0.57M 0.42M
Property plant equipment - 1.17M 0.16M - -
Total current assets 315.09M 393.64M 595.08M 11.16M 19.23M
Long term investments - - - - -
Net tangible assets - 336.17M 491.55M 3.10M -
Short term investments 128.52M - - - -
Net receivables 39.15M 26.72M 16.81M 2.93M -
Long term debt 75.70M 69.80M 75.70M - 3.62M
Inventory 0.00000M -29.99400M -17.80700M 1.00M -
Accounts payable 11.81M 13.84M 8.06M 1.03M -
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 1.49M -1.49700M 0.69M - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 2.55M 49.49M 34.39M 0.55M -
Deferred long term asset charges - - - - -
Non current assets total 47.88M 50.66M 34.55M 0.55M -
Capital lease obligations 8.89M - - - -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -0.93100M - 0.00000M 0.00000M
Change to liabilities 6.35M 3.80M -0.04900M 0.85M
Total cashflows from investing activities -0.93100M 63.26M 63.26M 63.26M
Net borrowings - 73.65M 1.36M 3.83M
Total cash from financing activities 0.46M 660.15M 1.36M 9.01M
Change to operating activities -9.18200M -9.82600M -0.49700M -1.92100M
Net income -216.20700M -381.07100M -10.66300M -5.06100M
Change in cash -201.43800M 590.12M -9.34300M 3.70M
Begin period cash flow 595.08M 4.97M 16.57M 12.87M
End period cash flow 393.64M 595.08M 7.23M 16.57M
Total cash from operating activities -200.54600M -135.10900M -10.63000M -5.82500M
Issuance of capital stock 0.00000M - 0.00000M 5.17M
Depreciation 0.13M 0.03M 0.03M 0.00600M
Other cashflows from investing activities 0.21M 0.21M 0.21M 0.21M
Dividends paid - - - -
Change to inventory - - - -
Change to account receivables - - - -
Sale purchase of stock - - 0.00100M 5.17M
Other cashflows from financing activities 0.46M 660.15M 1.36M 9.01M
Change to netincome 18.36M 251.74M 0.58M 0.30M
Capital expenditures 1.14M 0.19M 0.19M 0.19M
Change receivables - - - -
Cash flows other operating - - - -
Exchange rate changes - - - -
Cash and cash equivalents changes - - - -
Change in working capital -2.83100M 231.08M -0.48900M -1.00600M
Stock based compensation 24.96M 14.85M 0.34M 0.24M
Other non cash items -3.74700M 231.08M 0.19M -
Free cash flow -201.68300M -135.29500M -10.63000M -5.82500M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CNTA
Centessa Pharmaceuticals PLC ADR
0.41 2.70% 15.57 - - 165.69 4.82 141.03 -5.8426
NVO
Novo Nordisk A/S
1.59 2.02% 80.28 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S
- -% 78.60 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
3.93 0.93% 425.93 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc
3.68 0.54% 685.26 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

Centessa Pharmaceuticals PLC ADR

1 Ashley Road, Altrincham, United Kingdom, WA14 2DT

Key Executives

Name Title Year Born
Dr. Saurabh Saha M.D., Ph.D. CEO & Director 1977
Dr. Gregory M. Weinhoff M.B.A., M.D., MBA Principal Accounting Officer & CFO 1971
Dr. Antoine Yver M.D., M.Sc., MSc Exec. VP & Chairman of Devel. 1958
Dr. Thomas S. Templeman Ph.D. Chief Technology Officer 1960
Dr. David M. Chao Ph.D. Chief Admin. Officer 1968
Ms. Kristen K. Sheppard Esq., J.D. Sr. VP of Investor Relations & Corp. Communications NA
Mr. Iqbal J. Hussain L.L.B. Gen. Counsel, Chief Compliance Officer & Corp. Sec. 1981
Ms. Karen M. Anderson Chief People Officer 1967
Ms. Tia L. Bush Chief Quality Officer 1971
Dr. David John Grainger Ph.D. Chief Innovation Officer 1969

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.